Novocure (NVCR) Misses Q2 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
July 26, 2018 6:00 AM EDTQuarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018
Submission of local coverage determination reconsideration request to the durable medical equipment Medicare administrative contractors following June CMS announcement of new payment rules for durable medical equipment products
STELLAR data in mesothelioma will be presented at IASLC in late September
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the three and six months ended June 30, 2018. The company also highlighted continued commercial momentum for Optune and continued clinical development progress.
ÂSecond quarter 2018 highlights include:
... More